Background: Diclofenac is a widely used nonsteroidal anti-inflammatory drug. Recent
studies have shown that frequent consumption of this drug in high concentrations can cause heart diseases,
so strict control of diclofenac’s quantity in commercial drugs is necessary. This paper presents
the development of an optimized voltammetric methodology for the quantification of diclofenac,
which offers some advantages over other electrochemical and accepted methods.
Objective: Optimize with a Box-Behnken design the differential pulse voltammetry parameters towards
the quantification of diclofenac in pharmaceutical samples.
Methods: Diclofenac behavior in the working electrode was evaluated by cyclic voltammetry, in order
to stablish the best conditions for diclofenac’s quantification. A Box-Behnken design was then used to
optimize the differential pulse voltammetry parameters and stablish the analytical behavior of the proposed
methodology. Commercial tablets were prepared for analysis according to the Pharmacopeia,
the DPV optimized methodology was used to quantify diclofenac in the samples, and the results were
statistically compared with those obtained with the official methodology.
Results: After optimization, the analytical parameters found were: correlation coefficient of 0.998, detection
limit of 0.001 µM, quantification limit of 0.0033 µM and sensitivity of 0.299 µA.µM-1. The
statistical analysis showed there were no significant differences between the results obtained with the
proposed methodology and those obtained with the official methodology.
Conclusion: The statistical analysis showed that the proposed methodology is as reliable as the official
spectrophotometric one for the quantification of diclofenac in commercial drugs, with very competitive
analytical parameters, and even better to others found with more complex electrodes.